Halozyme Therapeutics (HALO) Debt to Equity Ratio: -58.84

Halozyme Therapeutics, Inc. (HALO)

100.67 -1.01 (-0.99%) USD | NASDAQ | Nov 12, 16:00

100.66 -0.01 (-0.01%) After-Hours: 07:42

Debt to Equity Ratio Chart

Historical Debt to Equity Ratio Data

View and export this data back to 2002. Start Trial.

Date	Value
September 30, 2026	-58.84
June 30, 2026	14.95
March 31, 2026	9.764
December 31, 2025	44.60
September 30, 2025	2.998
June 30, 2025	4.535
March 31, 2025	3.126
December 31, 2024	4.223
September 30, 2024	3.323
June 30, 2024	5.191
March 31, 2024	8.441
December 31, 2023	17.89
September 30, 2023	6.010
June 30, 2023	9.905
March 31, 2023	22.69
December 31, 2022	8.87
September 30, 2022	15.51
June 30, 2022	4.251
March 31, 2022	3.372
December 31, 2021	4.451
September 30, 2021	3.109
June 30, 2021	7.305
March 31, 2021	12.93
December 31, 2020	2.630
September 30, 2020	3.984

Date	Value
June 30, 2020	3.711
March 31, 2020	6.710
December 31, 2019	4.387
September 30, 2019	0.2602
June 30, 2019	0.3267
March 31, 2019	0.4053
December 31, 2018	0.5078
September 30, 2018	0.6109
June 30, 2018	0.6513
March 31, 2018	0.6985
December 31, 2017	0.9711
September 30, 2017	2.858
June 30, 2017	3.628
March 31, 2017	-3.659
December 31, 2016	-6.669
September 30, 2016	-17.69
June 30, 2016	20.98
March 31, 2016	6.651
December 31, 2015	1.159
September 30, 2015	1.566
June 30, 2015	0.9905
March 31, 2015	1.324
December 31, 2014	1.206
September 30, 2014	1.248
June 30, 2014	0.9008

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks